Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross' Stock Picks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other unknown billionaire Phill Gross' stock picks with huge upside potential.
Phillip 'Phill' Gross is a seasoned investor and influential figure in the world of institutional asset management, best known as the Co-founder, Managing Director, and Healthcare Portfolio Manager of Adage Capital Management. While Robert Atchinson, his longtime collaborator and fellow Co-founder, serves as the firm's Portfolio Manager, Gross's leadership and strategic vision have played a foundational role in shaping Adage's long-term investment philosophy and reputation. The two met in the mid-1980s while working as Harvard University's endowment analysts. Their professional synergy led them to leave Harvard Management Company in the 1990s, following public scrutiny over performance-based bonuses. With the backing of an initial $1.8 billion investment from Harvard and an agreement for the university to receive 10% of the firm's earnings, they launched Adage Capital Management in 2001 alongside an 18-person team.
Under Gross's co-leadership, Adage has become a key player in managing assets for prominent institutional clients such as Harvard University, Dartmouth College, Northwestern University, the American Red Cross, and the Getty Foundation. The firm specializes in long/short equity strategies guided by fundamental analysis and engages in risk arbitrage and event-driven opportunities when market conditions are favourable. Adage Capital Management and its predecessor, the Select Equity Group at Harvard Management Company, have consistently outperformed broader market benchmarks by an average of 3.5% over the past 15 years. This is a testament to the disciplined, research-driven investment framework that Gross helped instill.
Gross himself brings a deep background in healthcare investing, having served for nearly two decades at Harvard Management Company in various roles, including Healthcare and Retail Analyst, Equity Research Director, and Partner. His academic credentials include a B.S. in finance and economics (1982) and an M.S. in investments (1983), both from the University of Wisconsin. He remains actively engaged with his alma mater, serving on the advisory boards of the Steve Hawk Center for Applied Securities Analysis and the Nicholas Center for Applied Corporate Finance. In recognition of his professional accomplishments and ongoing contributions, Gross received the Distinguished Alumnus Award from the University of Wisconsin Business School in 2006.
Beyond finance, Gross is a committed philanthropist. He co-founded Strategic Grant Partners, an organization focused on driving systemic change in education and family services throughout Massachusetts. He also serves as Vice President of the Board of Directors for Youth Enrichment Services, a nonprofit that provides urban youth with outdoor recreational experiences. In addition, he holds board positions with the U.S. Ski and Snowboard Association, where he is Vice-Chair of the Investment Committee, and with the T2 Foundation.
Adage Capital Management's latest 13F filing for Q4 2024 reported $57.19 billion in managed securities, with the top 10 holdings comprising 31.7% of the total portfolio, demonstrating a strategic yet diversified approach to asset allocation. While Atchinson oversees day-to-day portfolio management, Gross's enduring influence and expertise, particularly in healthcare investing, continue to shape the firm's long-term success and institutional credibility.
We searched through Adage Capital Management's Q4 2024 13F filings to identify unknown billionaire Phill Gross' stock picks with the highest upside potential. We compiled the equities with upside potential higher than 34% at the time of writing this article and discussed why they stood out as strong potential investments. Finally, we ranked the stocks based on the ascending order of their upside potential. To assist readers with more context, we mentioned the hedge fund sentiment around each stock using data from 1,009 hedge funds tracked by Insider Monkey in the fourth quarter of 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points ().
A rack of test tubes and beakers being stirred in a laboratory, as researchers analyze the data.Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company dedicated to advancing innovative immunotherapies designed to generate tumor-specific immune responses. The company focuses on therapies that target and destroy cancer cells while sparing healthy tissue, thereby minimizing adverse effects often associated with traditional cancer treatments.
Financially, Janux Therapeutics, Inc. (NASDAQ:JANX) demonstrated a robust capital position at the close of 2024. As of December 31, the company reported $1.03 billion in cash, cash equivalents, and short-term investments, a substantial increase from $344.0 million reported at the end of 2023. This significant boost in financial reserves positions Janux to sustain and accelerate its research efforts over the coming years. The company's research and development expenses rose to $20.8 million for the fourth quarter and totalled $68.4 million for the year, compared to $12.2 million and $54.9 million for the same periods in 2023, reflecting intensified clinical activity and investment in its pipeline. Likewise, general and administrative expenses grew to $8.2 million for the quarter and $41.0 million for the full year, up from $6.4 million and $26.1 million in the prior year, as the company expanded its operational infrastructure to support clinical development and long-term growth.
Despite increased expenditures, Janux Therapeutics, Inc. (NASDAQ:JANX) reported a net loss of $20.2 million for the fourth quarter and $69.0 million for the full year of 2024, compared to $11.8 million and $58.3 million in 2023. These figures are consistent with a company in the clinical development phase, where investments in research, trials, and infrastructure precede revenue generation. The increased losses correspond with the company's strategic ramp-up of its therapeutic programs and development pipeline. Janux remains well-capitalized and committed to advancing its mission of delivering transformative immunotherapies that leverage tumor-specific biology to safely and effectively combat cancer.
In the fourth quarter of 2024, Adage Capital Management significantly increased its investment in Janux Therapeutics, Inc. (NASDAQ:JANX), increasing its position to over 3 million shares—a 48% rise from the 2.08 million shares held in the previous quarter. This expansion brought the fund's total stake in the company to an estimated $1.6 billion.
Overall, JANX ranks 1st on our list of unknown billionaire Phill Gross' stock picks with huge upside potential. While we acknowledge the potential of JANX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than JANX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Is Nvidia stock a massive bargain — or a massive value trap?
AI has transformed demand for computer chips and the most obvious beneficiary of that has been Nvidia (NASDAQ: NVDA). With a stock market capitalization of $3.4trn, Nvidia might not seem like an obvious bargain. But what if it is really worth that much – or potentially a lot more? I have been keen to add some Nvidia stock to my portfolio, but I do not want to overpay. After all, Nvidia has shot up 1,499% in five years! So, here is what I am doing. For some companies in which I have invested in the past, from Reckitt to Burberry, I have benefited as an investor from a market being mature. Sales of detergent or pricy trenchcoats may grow over time, but they are unlikely to shoot up year after year. That is because those firms operate in mature markets. On top of that, as they are large and long-established, it is hard for them to grow by gaining substantial market share. So, market maturity has helped me as an investor because it has made it easier for me to judge what I think the total size of a market for a product or service may be – and how much of it the company in question looks likely to have in future. Chips, by contrast, are different. Even before AI, this was still a fast-growing industry – and AI has added fuel to that fire. On top of that, Nvidia is something of a rarity. It is already a large company and generated $130bn in revenues last year. But it is not mature – rather, it continues to grow at a breathtaking pace. Its first-quarter revenue was 69% higher than in the same three months of last year. Those factors mean that it is hard to tell what Nvidia is worth. Clearly that is not only my opinion: the fact that Nvidia stock is 47% higher than in April suggests that the wider market is wrestling with the same problem. Could it be a value trap? It is possible. For example, chip demand could fall after the surge of recent years and settle down again at a much lower level. A lower cost rival could eat badly into Nvidia's market share. Trade disputes could see sales volumes fall. With a price-to-earnings (P/E) ratio of 46, just a few things like that going wrong could mean today's Nvidia stock price ends up looking like a value trap. On the other hand, think about those first-quarter growth rates. If Nvidia keeps doing as well, let alone better, its earnings could soar. In that case, the prospective P/E ratio based on today's share price could be low and the current share price a long-term bargain. I see multiple possible drivers for such an increase, such as more widespread adoption of AI and Nvidia launching even more advanced proprietary chip designs. So, I reckon the company could turn out to be either a massive bargain at today's price, or a massive value trap. The price does not offer me enough margin of safety for my comfort if the stock is indeed a value trap. So, I will wait for a more attractive valuation before buying. The post Is Nvidia stock a massive bargain — or a massive value trap? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Burberry Group Plc, Nvidia, and Reckitt Benckiser Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Forbes
an hour ago
- Forbes
Is Lululemon's Recent Pullback Your Perfect Entry Point?
CHINA - 2025/04/17: A shopper walks past the Canadian sportswear clothing band Lululemon store. ... More (Photo by Sebastian Ng/SOPA Images/LightRocket via Getty Images) Lululemon stock (NASDAQ:LULU) is currently trading at approximately $331 and seems undervalued based on its strong fundamentals, even though the stock often experiences volatility during turbulent market conditions. The company provided impressive Q1 2025 results, with revenue increasing by 7% to $2.37 billion and EPS rising to $2.60, just surpassing expectations. However, the market concentrated on a weaker-than-anticipated 1% increase in same-store sales and a revised full-year outlook, influenced in part by tariff-related pressures. The consequence? A swift 22% decline in after-hours trading that reflects more about short-term market sentiment than long-term intrinsic value. In spite of its high-performance profile, LULU behaves like a value stock. Lululemon trades at about 18x its trailing earnings (slightly lower than the historical average) and 19x price-to-free cash flow – both figures are beneath the S&P 500's averages—yet it is a company that consistently excels in revenue, margins, and return on capital. In comparison with its main competitor Nike, Lululemon is more affordable across significant profit metrics, with a reduced P/E and a more appealing P/FCF ratio. Investors are essentially acquiring Ferrari performance at Lexus pricing. Moreover, with a $32 billion market cap generating $1.6 billion in trailing free cash flow—a 5% cash flow yield, LULU appears to be more of a long-term wealth builder than a fluctuating apparel brand. For those looking for lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and yielding returns exceeding 91% since inception. Lululemon continues to showcase its growth capabilities. The company reports an impressive three-year revenue CAGR of 19%, which is more than three times the S&P 500's 5.5%. Over just the past year, it demonstrated 10% revenue growth, increasing annual sales to about $11 billion. Despite encountering macroeconomic challenges, the brand persists as a global growth powerhouse with an expanding international presence and remarkable efficiency. Its operating margin over the last four quarters of 23.7% nearly doubles the S&P 500's 13.2%, while its operating cash flow and net income margins (21.5% and 17.1%, respectively) significantly outperform broader market averages. These figures are not merely good—they're elite. Lululemon's balance sheet resembles a fortress. With a debt-to-equity ratio of just 4.9%, it is significantly below the S&P 500 average of 19.9%. Additionally, its cash-to-assets ratio of 26.1% far exceeds the market's 13.8%. This immaculate financial status provides Lululemon with both strength during downturns and the ability to invest in further growth. There's no way to sugarcoat it: Lululemon has experienced dramatic declines during market corrections. It dropped 46% during the downturn of 2022 (compared to the S&P's 25%), fell 47% in the early 2020 COVID-19 shock (versus 34%), and was extremely affected during the 2008 crash, plummeting 92% (compared to 57%). Investors must recognize that with LULU, strong fundamentals don't necessarily provide protection against sharp changes in sentiment. Our dashboard How Low Can Stocks Go During A Market Crash illustrates how major stocks performed during and after the last six market crashes. Lululemon checks nearly every box: strong growth, solid profitability, and a fortified balance sheet, with the only drawback being its susceptibility during market downturns. Trading at a slight discount relative to its strong performance profile, the recent Q1 results, which included mixed outcomes and cautious guidance, underscore immediate challenges while preserving the integrity of long-term fundamentals. Nonetheless, you could also consider the Trefis Reinforced Value (RV) Portfolio, which has surpassed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to yield strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid- and small-cap RV Portfolio stocks offered a responsive strategy to capitalize on positive market conditions while limiting losses during downturns, as detailed in RV Portfolio performance metrics.
Associated Press
2 hours ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
